A German pharmaceutical company distributed thousands of unlabeled doses of thalidomide to U.S. doctors in the early 1960s without proper tracking or safety monitoring, resulting in children born with severe limb deformities despite the FDA’s refusal to formally approve the sedative for general use.
The drug was handed out to treat various conditions including morning sickness, but doctors often failed to inform patients they were receiving thalidomide or document its use in medical records. When deformed children were born, physicians frequently did not reveal they had administered the drug, and some women were explicitly told they had not taken it. This lack of documentation has made it difficult for survivors to prove their exposure decades later.
While the thalidomide tragedy in other countries like Germany and Britain is well-documented, American survivors have struggled for recognition. The FDA formally acknowledges only 17 U.S. thalidomide survivors, though researchers estimate the actual number could be around 100. Survivors describe encountering doctors today who deny the drug was ever distributed in the United States, despite evidence that significant quantities were distributed through unregulated clinical trials with poor record-keeping.
The advocacy group USA Thalidomide Survivors, founded in 2018, is pushing Congress to pass legislation that would officially acknowledge American survivors and provide each with $150,000 in compensation, with potential for additional support. Advocates emphasize that the United States remains the only developed nation that has not provided any formal recognition or support to thalidomide survivors. As survivors age and their health deteriorates, they are seeking both acknowledgment of their existence and tangible assistance.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI